Attached files

file filename
10-K - China Yongxin Pharmaceuticals Inc.v177274_10k.htm
EX-31.2 - China Yongxin Pharmaceuticals Inc.v177274_ex31-2.htm
EX-31.1 - China Yongxin Pharmaceuticals Inc.v177274_ex31-1.htm
EX-21.1 - China Yongxin Pharmaceuticals Inc.v177274_ex21-1.htm
EX-10.17 - China Yongxin Pharmaceuticals Inc.v177274_ex10-17.htm
EX-10.14 - China Yongxin Pharmaceuticals Inc.v177274_ex10-14.htm
EX-10.13 - China Yongxin Pharmaceuticals Inc.v177274_ex10-13.htm
EX-10.15 - China Yongxin Pharmaceuticals Inc.v177274_ex10-15.htm
EX-10.16 - China Yongxin Pharmaceuticals Inc.v177274_ex10-16.htm
 
Exhibit 32.1
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the report of China Yongxin Pharmaceuticals Inc. (the “Company”) on Form 10-K for the period ending December 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Yongxin Liu
Yongxin Liu
Chief Executive Officer
March 30, 2010
 
/s/ Harry Zhang
Harry Zhang
Chief Financial Officer
March 30, 2010
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.